Odyssey Therapeutics, Inc. filed a Form 8-K on September 8, 2026, to furnish Exhibit 99.1, a corporate presentation posted on its investor website. The presentation details the company's pipeline of oral therapies for inflammatory and autoimmune diseases, including OD-001 (RIPK2 inhibitor) for ulcerative colitis and Crohn’s disease, OD-002 (SLC15A4 inhibitor) for cutaneous lupus erythematosus, and OD-003 (TNFR2 agonist). It reports $433 million in cash as of June 30, 2026, with an expected funding runway into the second half of 2028. The filing outlines clinical milestones such as updated monotherapy data for OD-001 at UEG Week in October 2026 and a CTA filing for OD-002 in H2 2026. Odyssey Therapeutics, Inc. operates in the biotechnology industry, developing small molecule and protein therapies targeting inflammatory and autoimmune diseases.

Odyssey Therapeutics reported financial results for the second quarter ended June 30, 2026, reporting a net loss of $52.8 million compared to $41.2 million in the prior year period. Research and development expenses increased to $36.2 million from $30.2 million, while general and administrative expenses decreased to $10.5 million from $13.2 million. The company held $433.1 million in cash as of June 30, 2026, which is expected to fund operations into the second half of 2028. Clinically, data from the Phase 2a monotherapy trial of OD-001 was accepted for presentation at United European Gastroenterology Week in October. The company anticipates initiating a Phase 2b monotherapy trial and a Phase 2a combination trial with vedolizumab in the second half of 2026, alongside plans to file a clinical trial application for its second program, OD-002, by year-end. Odyssey Therapeutics is a clinical-stage biopharmaceutical company developing medicines for autoimmune and inflammatory diseases.

Odyssey Therapeutics, Inc. posted a corporate presentation on its website on June 23, 2026. The presentation is furnished as Exhibit 99.1. Odyssey Therapeutics, Inc. is a biotechnology company focused on developing therapeutic solutions.

Odyssey Therapeutics, Inc. announced its financial results for the quarter ended March 31, 2026, on June 17, 2026. The company is a biotechnology company focused on developing therapeutic solutions for inflammatory and inflammatory-driven diseases.